Welcome to our dedicated page for Dassault Systemes news (Ticker: DASTY), a resource for investors and traders seeking the latest updates and insights on Dassault Systemes stock.
Dassault Systèmes SA reports company news centered on its 3DEXPERIENCE platform, virtual twins, and software activity across manufacturing industries, life sciences and healthcare, and infrastructure and cities. Updates commonly cover software revenue, cloud activity, annual run-rate trends, operating cash flow, margin performance, and product themes such as SOLIDWORKS, CENTRIC, 3D UNIV+RSES, and industrial AI.
Company announcements also address shareholder and governance matters, including combined shareholders’ meetings, Universal Registration Document filings with the Autorité des marchés financiers, share repurchase program descriptions, dividend proposals, outstanding share and voting-right declarations, and board leadership changes.
Dassault Systèmes (Ticker: DASTY) declared its total number of outstanding shares and voting rights as of February 28, 2026. The company reported 1,341,855,657 outstanding shares and 2,013,481,153 voting rights.
The voting rights figure is calculated on the basis of all outstanding shares, including those with suspended voting rights, pursuant to applicable AMF rules. Shareholders requiring threshold declaration details are invited to contact Investor Relations.
Dassault Systèmes (DASTY) announced that Pascal Daloz, current Chief Executive Officer, becomes Chairman and Chief Executive Officer effective February 21, 2026, after the Board’s unanimous decision. Bernard Charlès is stepping down as Executive Chairman and Board member for personal reasons but will remain available to support the 3D UNIV+RSES AI ambition. A conference call is scheduled for February 23, 2026, at 7:00 am London time / 8:00 am Paris time.
This governance change aims to continue leadership continuity while advancing the company’s Industrial AI strategy.
Dassault Systèmes (OTC:DASTY) disclosed repurchases of its ordinary shares under the buyback program decided by the May 22, 2025 general meeting. The company bought a total of 3,500,000 shares during February 12–13, 2026 across multiple markets at weighted average prices near €18.03–€18.13.
Transactions are reported by trading day and market, and investor relations contact details were provided for threshold crossing declarations.
Dassault Systèmes (DASTY) reported Q4 2025 total revenue up 1% to €1.68B and FY25 total revenue up 4% to €6.24B. FY25 non-IFRS operating margin was 32.0% and non-IFRS diluted EPS was €1.31. ARR reached €4.50B, up 6% year-over-year. The company initiated 2026 non-IFRS guidance: revenue growth 3–5%, operating margin 32.2–32.6%, and diluted EPS €1.30–€1.34. Management highlighted subscription and Cloud momentum, Industrial AI initiatives, and a strategic partnership with NVIDIA.
Dassault Systèmes (DASTY) declared its total number of outstanding shares and voting rights as of January 31, 2026. The company reported 1,341,809,943 outstanding shares and 2,013,517,837 voting rights. Shareholders are directed to declaration rules under AMF articles and contact Investor Relations for threshold notifications.
Dassault Systèmes (DASTY) published the half-year statement for its liquidity contract with Oddo BHF SCA as of December 31, 2025. The liquidity account held 925,197 shares and €5,384,754.01 in cash on that date. The contract was implemented on January 7, 2015 and amended with cash contributions on October 26, 2017 (+€5,000,000) and December 13, 2018 (+€5,000,000). At the June 18, 2019 implementation of the new contract the account showed 62,557 shares and €17,496,140.38 in cash. From July 1, 2025 to December 31, 2025 the liquidity activity comprised 20,126 purchases and 22,371 sales, with volumes of 4,863,746 shares bought (€128,747,093) and 4,796,309 shares sold (€128,114,812.54).
Dassault Systèmes (Ticker: DASTY) reported the total number of outstanding shares and voting rights as of December 31, 2025. The company stated 1,341,806,268 outstanding shares and 2,013,578,477 voting rights.
The release notes that the voting-rights total is calculated on the basis of all outstanding shares, including those whose voting rights are suspended, pursuant to Article 223-11 of the General Regulation of the Autorité des marchés financiers. Shareholders are directed to the investor relations contact for threshold-declaration procedures.
Dassault Systèmes (OTC:DASTY) announced the total number of outstanding shares and voting rights as of November 30, 2025. The company reported 1,341,782,567 outstanding shares and 2,013,594,540 voting rights.
The release notes that voting rights are calculated on the basis of all outstanding shares, including those with suspended voting rights, under Article 223-11 of the Autorité des marchés financiers General Regulation. Shareholders are invited to consult the referenced article for thresholds and to send declarations about threshold crossings to the Investor Relations Service or via Investors@3ds.com.
Dassault Systèmes (DASTY) declared the total number of outstanding shares and voting rights as of October 31, 2025. The company reported 1,341,772,015 outstanding shares and 2,013,588,275 voting rights. The voting-rights total is calculated on the basis of all outstanding shares, including those with suspended voting rights, under Article 223-11 of the AMF General Regulation.
The company reminded shareholders of threshold-declaration rules under Articles 223-16 and 221-3 and provided contact details for the Investor Relations Service for notifications and questions.
Dassault Systèmes (OTC:DASTY) announced that its Medidata brand has extended a 10-plus-year collaboration with Sanofi to support clinical research and speed therapy development. Sanofi will use Medidata Patient, Data, and Study Experiences, including AI-embedded, platform-based solutions and decentralized trial capabilities, with Medidata supplying consulting and end-to-end operational support. The extension aims to unify clinical workflows, reduce silos, and shorten delays to accelerate new therapies and improve patient journeys.